Abstract
The involvement of the 20S proteasome in the degradation of critical intracellular regulatory proteins has suggested the potential use of proteasome inhibitors as novel therapeutic agents being applicable in many different disease indications. Early synthetic inhibitors of the 20S proeteasome were relatively nonspecific compounds but proved to be invaluable probes for improving our understanding of the ubiquitin/proteasomedependent degradation pathway in vitro. New classes of inhibitors that target this proteolytic enzyme have emerged in the last few years by combining traditional drug discovery approaches with new methods to find and optimize lead structures. This chapter reviews recent salient medicinal chemistry achievements in the design, synthesis, and biologic characterization of a variety of inhibitors of the 20S proteasome. These compounds are capable of modulating the subunit-specific proteolytic activities of the 20S proteosome in ways not previously possible. Examples have been selected to illustrate the impact of structural-based design and natural product screening in this area of research.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
García-Echeverría C. Recent advances in the identification and development of 20S proteasome inhibitors. Mini Rev Med Chem 2002;2:247–259.
Myung J, et al. The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 2001;21:245–273.
Kisselev AF, etal. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001;8:739–758.
Adams J. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol Med 2002;8:S49—S54.
Adams J. Proteasome inhibition in cancer: development of PS-341. Semin Oncol 2001;28:613–619.
Mundy GR, inventor; Osteoscreen Inc, assignee. Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors. WO 0061167, 2000.
Anma T, et al, inventors; Takeda Chemical Industries, Ltd, assignee. Preparation of dipeptides and proteasome inhibitors. JP 11292833, 1999.
McCormack TA, et al. Kinetic studies of the branched chain amino acid preferring peptidase activity of the 20S proteasome: development of a continuous assay and inhibition by tripeptide aldehydes and clasto-lactacystin beta-lactone. Biochemistry 1998;37:7792–7800.
Stein RL, et al, inventors; ProScript, Inc, assignee. Preparation of peptide aldehyde derivatives as inhibitors of the 26S proteolytic complex and the 20S proteasome. US 5693617, 1997.
Iqbal M, et al. Potent inhibitors of proteasome. J Med Chem 1995;38:2276–2277.
Figueiredo-Pereira ME, et al. A new inhibitor of the chymotrypsin-like activity of the multicatalytic proteinase complex (20S proteasome) induces accumulation of ubiquitin-protein conjugates in a neuronal cell. J Neurochem 1994;63:1578–1581.
Figueiredo-Pereira ME, et al. Comparison of the effect of calpain inhibitors on two extralysosomal proteinases: the multicatalytic proteinase complex and m-calpain. J Neurochem 1994;62:1989–1994.
Rock KL, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994;78:761–771.
Wilk S, et al. Evidence that pituitary cation-sensitive neutral endopeptidase is a multicatalytic protease complex. J Neurochem 1983;40:842–849.
An B, et al. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 1998;5:1062–1075.
Loidl G, et al. Bifunctional inhibitors of the trypsin-like activity of eukaryotic proteasomes. Chem Biol 1999;6:197–204.
Loidl G, et al. Synthesis of bivalent inhibitors of eucaryotic proteasomes. J Pept Sci 2000;6:36–46.
Loidl G, et al. Bivalent inhibitors of the yeast proteasome. Proc Eur Pept Symp 1999;828–829.
Okada K, et al. 4-Hydroxy-2-nonenal-mediated impairment of intracellular proteolysis during oxidative stress. Identification of proteasomes as target molecules. J Biol Chem 1999;274:23787–23793.
Conconi M, et al. Proteasome inactivation upon aging and on oxidation effect of HSP 90. Mol Biol Rep 1997;24:45–50.
Momose I, et al. Tyropeptins A and B, new proteasome inhibitors produced by Kitastospora sp. MK993-dF2 I. Taxonomy, isolation, physico-chemical properties and biological activities. J Antibiot 2001;54:997–1003.
Momose I, et al. Tyropeptins A and B, new proteasome inhibitors produced by Kitasatospora sp. MK993-dF2 II. Structure determination and synthesis. J Antibiot 2001;54:1004–1012.
Lynas JF, et al. Inhibitors of the chymotrypsin-like activity of proteasome based on di- and tri-peptidyl a-keto aldehydes (glyoxals). Bioorg Med Chem Lett 1998;18:373–378.
Chatterjee S, et al. P’-extended alpha-ketoamide inhibitors of proteasome. Bioorg Med Chem Lett 1999;9:2603–2606.
Wang L, et al, inventors; CV Therapeutics Inc, assignee. a-Ketoamide inhibitors of 20S proteasome. WO 9937666, 1999.
Adams J, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615–2622.
Adams J, et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 1998;8:333–338.
Adams J, et al., inventors; ProScript, Inc, assignee. Boronic ester and acid compounds, synthesis and uses. WO 9613266, 1996.
Siman R, et al., inventors; Cephalon Inc, assignee. Multicatalytic protease inhibitors for use as antitumor agents. WO 9930707, 1999.
Palmer JT. Vinyl sulfones as mechanism-based cysteine protease inhibitors. J Med Chem 1995;38:3193–3196.
Bogyo M, et al. Covalent modification of the active site threonine of proteasomal β-subunits and the Escherichia coli homolog Hs1V by a new class of inhibitors. Proc Natl Acad Sci USA 1997;94:6629–6634.
Bogyo M, et al. Substrate binding and sequence preference of the proteasome revealed by active-sitedirected affinity probes. Chem Biol 1998;5:307–320.
Nazif T, et al. Global analysis of proteasomal substrate specificity using positional-scanning libraries of covalent inhibitors. Proc Nall Acad Sci USA 2001;98:967–2972.
Kessler BM, et al. Extended peptide-based inhibitors efficiently target the proteasome and reveal overlapping specificities of the catalytic β3-subunits. Chem Biol 2001;8:913–929.
Lehr P, et al. Inhibitors of human immunodeficiency virus type 1 protease containing 2-aminobenzylsubstituted 4-amino-3-hydroxy-5-phenylpentanoic acid: synthesis, activity, and oral bioavailability. J Med Chem 1996;39:2060–2067.
Billich A, et al. Potent and orally bioavailable HIV-1 proteinase inhibitors containing the 2-aminobenzylstatine moiety. Antiv Chem Chemother 1995;6:327–336.
Scholz D, et al. Inhibitors of the HIV-1 proteinase containing 2-heterosubstituted-4-amino-3-hydroxy5-phenylpentanoic acid: synthesis, enzyme inhibition, and antiviral activity. J Med Chem 1994;37:3079–3089.
García-Echeverría C, et al. A new structural class of non-covalent and selective inhibitors of the chymotrypsin-like activity of the 20S proteasome. Bioorg Med Chem Lett 2000;11:1317–1319.
Groll M, et al. Structure of 20S proteasome from yeast at 2.4 Å resolution. Nature 1997;386:463–471.
Loewe J, et al. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 Å resolution. Science 1995;268:533–539.
Furet P, et al. Modeling of the binding mode of a non-covalent inhibitor of the 20S proteasome. Application to structure-based analogue design. Bioorg Med Chem Lett 2001;11:1321–1324.
Furet P, et al. Structure-based optimisation of 2-aminobenzylstatine derivatives: potent and selective inhibitors of the chymotrypsin-like activity of the human 20S proteasome. Bioorg Med Chem Lett 2002;12:1331–1334.
Lum RT, et al. Selective inhibition of the chymotrypsin-like activity of the 20S proteasome by — methoxy-1-indanone dipeptide benzamides. Bioorg Med Chem Lett 1998; 8:209–214.
Lum RT, et al. A new structural class of proteasome inhibitors that prevent NF-κ activation. Biochem Pharmacol 1998;55:1391–1397.
Andre P, et al, inventors; INSERM, assignee. Novel use of HIV protease inhibiting compounds. WO 9963998, 1999.
Andre P, et al. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci USA 1998;95:13120–13124.
Retterstol K, et al. Results of intensive long-term treatment of familial hypercholesterolemia. Am J Cardiol 1996;78:1369–1374.
Rao S, et al. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci USA 1999;96:7797–7802.
Figueiredo-Pereira ME, et al. The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20S proteasome. J Biol Chem 1996;271:16455–16459; Erratum in: J Biol Chem 1996;271:23602.
Meyer S, et al. Cyclosporine A is an uncompetitive inhibitor of proteasome activity and prevents NF-κ activation. FEBS Lett 1997;413:354–358.
Piccinini M, et al. Proteasomes are a target of the anti-tumour drug vinblastine. Biochem J 2001;356:835–841.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer Science+Business Media New York
About this chapter
Cite this chapter
García-Echeverría, C. (2004). Other Proteasome Inhibitors. In: Adams, J. (eds) Proteasome Inhibitors in Cancer Therapy. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-794-9_5
Download citation
DOI: https://doi.org/10.1007/978-1-59259-794-9_5
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61737-452-4
Online ISBN: 978-1-59259-794-9
eBook Packages: Springer Book Archive